Prelude Capital Management’s Twist Bioscience TWST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-18,976
Closed -$1.95M – 1638
2026
Q2
$1.95M Sell
18,976
-2,711
-13% -$176K 0.14% 183
2026
Q1
$1.03M Sell
21,687
-348
-2% -$15.6K 0.08% 298
2025
Q4
$699K Buy
+22,035
New +$687K 0.05% 414
2022
Q1
– Sell
-2,773
Closed -$215K – 2245
2021
Q4
$215K Sell
2,773
-327
-11% -$33.6K 0.01% 1527
2021
Q3
$332K Buy
+3,100
New +$355K 0.01% 1088
2021
Q2
– Sell
-5,324
Closed -$659K – 1971
2021
Q1
$659K Sell
5,324
-1,704
-24% -$259K 0.02% 776
2020
Q4
$993K Sell
7,028
-3,286
-32% -$365K 0.03% 481
2020
Q3
$784K Sell
10,314
-12,566
-55% -$782K 0.04% 315
2020
Q2
$1.04M Buy
+22,880
New +$821K 0.06% 313

Other funds holding TWST

Prelude Capital Management's TWST Position: Q3 2026 in Review

Prelude Capital Management sold out of Twist Bioscience (TWST) in Q3 2026, closing a stake of 18,976 shares — an estimated $1.95M sold.

Prelude Capital Management first reported a position in TWST in Q2 2020 and held it in 9 quarters. The position peaked at $1.95M in Q2 2026. 435 funds tracked by Wall St. Rank hold TWST as of Q3 2026.

  • Prelude Capital Management reported no remaining Twist Bioscience position as of Q3 2026 after selling out during the quarter.
  • Prelude Capital Management sold 18,976 Twist Bioscience shares in Q3 2026, an estimated $1.95M.
  • Prelude Capital Management first reported a position in Twist Bioscience in Q2 2020 and held it in 9 quarters.
  • Prelude Capital Management's Twist Bioscience position peaked at $1.95M in Q2 2026.
  • 435 funds tracked by Wall St. Rank held Twist Bioscience as of Q3 2026.

Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.